1335227-37-6

Basic information

• Product Name: (10S)-10-[(2R)-(acetyloxy)(phenyl)ethanoate]-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide
• Synonyms: (10S)-10-[(2R)-(acetyloxy)(phenyl)ethanoate]-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide
• CAS NO: 1335227-37-6
• Molecular Weight: 430.46
• Mol File: 1335227-37-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (10S)-10-[(2R)-(acetyloxy)(phenyl)ethanoate]-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (10S)-10-[(2R)-(acetyloxy)(phenyl)ethanoate]-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide(1335227-37-6)
• EPA Substance Registry System: (10S)-10-[(2R)-(acetyloxy)(phenyl)ethanoate]-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide(1335227-37-6)

Safety Data

• Hazardous Substances Data: 1335227-37-6(Hazardous Substances Data)

Upstream product

• 21737-58-6 10,11-dihydro-5H-dibenzo[b,f]azepin-10-one 
• 36507-30-9 carbamazepine 10,11-epoxide 
• 298-46-4 carbamazepin 
• 29331-92-8 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide 
• 51019-43-3 (R)-(-)-O-acetylmandelic acid 

Downstream Products

• 104746-04-5 S-licarbazepine 
• 186694-45-1 eslicarbazepine acetate 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

The invention relates to the compounds of formula I and formula IA or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I and formula IA; and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder (ADHD), schizophrenia, neuropathic pain, seizures, bipolar disorder, mania, phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotonia, intermittent explosive disorder, borderline personality disorder, Myotonia congenita and post-traumatic stress disorder.

PROCESS FOR PREPARATION OF ENANTIOMERS OF LICARBAZEPINE

The present invention provides a process for the preparation of eslicarbazepine and rlicarbazepine and their acetates by resolution of racemic licarbazepine using acetyl mandelic acid.